21 results on '"Byrtek, M."'
Search Results
2. Fluoridation and tooth wear in Irish adults
3. Interim Safety Results from Steam: a Randomized Phase 2 Trial of Sequential and Concurrent Folfoxiri–Bevacizumab (Bev) Vs Folfox–Bev for the First-Line (1L) Treatment (Tx) of Patients (Pts) with Metastatic Colorectal Cancer (Mcrc)
4. Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study.
5. Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): A U.S. patient cohort treated predominantly in community practices.
6. Abstract P6-12-03: Meta-Analysis of Patients with Triple-Negative Breast Cancer (TNBC) from Three Randomized Trials of First-Line Bevacizumab (BV) and Chemotherapy Treatment for Metastatic Breast Cancer (MBC)
7. 521P - Interim Safety Results from Steam: a Randomized Phase 2 Trial of Sequential and Concurrent Folfoxiri–Bevacizumab (Bev) Vs Folfox–Bev for the First-Line (1L) Treatment (Tx) of Patients (Pts) with Metastatic Colorectal Cancer (Mcrc)
8. An adaptation of ridge regression for improved estimation of kinetic model parameters from PET studies
9. Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: Report from the National LymphoCare Study.
10. An adaptation of ridge regression for improved estimation of kinetic model parameters from PET studies.
11. Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma.
12. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.
13. Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
14. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
15. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS).
16. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.
17. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States.
18. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States.
19. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States.
20. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
21. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.